Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?
Investors are always looking for stocks that are poised to beat at earnings season and Agios Pharmaceuticals, Inc. AGIO may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Agios Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for AGIO in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.48 per share for AGIO, compared to a broader Zacks Consensus Estimate of a loss of $1.51 per share. This suggests that analysts have very recently bumped up their estimates for AGIO, giving the stock a Zacks Earnings ESP of +1.99% heading into earnings season.
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Agios Pharmaceuticals, Inc. Price and EPS Surprise | Agios Pharmaceuticals, Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that AGIO has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Agios Pharmaceuticals, and that a beat might be in the cards for the upcoming report.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
